Diminished protein binding capacity of uremic sera for valproate following hemodialysis: Role of free fatty acids and uremic compounds

American Journal of Nephrology

Volumn 16, Issue 4, 1996, Pages 327-333

  Dasgupta, Amitava ^a   Jacques, Monique ^b   Malhotra, Deepak ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Free fatty acids; Uremia; Valproic acid

Indexed keywords

ACTIVATED CARBON; ANTICONVULSIVE AGENT; FATTY ACID; PHENYTOIN; PROTEIN; VALPROIC ACID;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; HEMODIALYSIS; HUMAN; PRIORITY JOURNAL; UREMIA;

EID: 0029931117     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000169018     Document Type: Article

References (16)

1. Bourgeois BFD: Valproate clinical use: in Levy R. Mattson R. Mcldrum B. Penry JK. Dreifuss Et (eds): Antiepilcptic Drugs. New York. Raven Press. 1989. pp 633-642.
2. Vajda F, Dummer O, Morris P, et al: Gas chromatographic measurement of plasma levels of sodium valproate: Tentative therapeutic range of a new anticonvulsant in the treatment of refractory epileptics. Clin Exp Pharmacol Ther 1978:5:67-73.
3. Cramer JA, Mattson RH, Bennett DM, Swick CT: Variable free and total valproic acid concentrations in sole and multidrug therapy. The DrugMonit 1986:8:411-415.
4. Scheyer RD, Cramer JA, Toftness BR, Hocholer JM, Mattson RH: In vivo determination of valproate binding constants during sole and mullidrug therapy. Ther Drug Monit 1990:12: 117-123.
5. Lenn NJ, Robertson M: Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy. Neurology 1992:42: 988-990.
6. Miles MV, Snead OC, Thom MD: Predictability of unbound antiepileptic drug concentrations in children treated with valproic acid and phenytoin. Clin Pharm 1988:7:688-693.
7. Bruni J, Wang LH, Marbury TC, Lee CS, Wilder BJ: Protein binding of valproic acid in uremic patients. Neurology 1980;30:557-559.
8. Sjoholm I, Kober A, Odar-Cederlof I, Borga O: Protein binding of drugs in uremic and normal serum: The role of endogenous binding inhibitors. Biochem Pharmacol 1976;25:1205-1213.
9. McNamara PJ, Laika D, Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 1981:98: 730-740.
10. Belpaire FM, Bogaert MG, Musche MM: Influence of renal failure on protein binding of drugs in animals and man. Eur J Clin Pharmacol 1977;11:27-32.
11. Reidenberg MM, Drayer DE: Alteration of drug protein binding in renal disease. Clin Pharmacokinct 1984;9(suppl 1): 18-26.
12. Dasgupta A, Abu-Alfa A: Increased free phenytoin concentrations in pre-dialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds. Am J Clin Pathol 1991:98: 19-25.
13. Chen R: Removal of fatty acids from scrum by charcoal treatment. J Biol Chem 1967:242: 178-181.
14. Patel IH, Levy RH: Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia 1979:20:85-90.
15. Craig WA, Evcnson MA, Sarver KP, Wagnild JP: Correction of protein binding defect in uremic serum by charcoal treatment. J Lab Clin Med 1976:87:637-647.
16. Depner TA, Gulyassy PF: Plasma protein binding in uremia: Extraction and characterization of an inhibitor. Kidney Int 1980:18:86-94.